Atlas Trials

OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

Clinical trial NCT05949021 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05949021
Sponsor
Mridula George, MD
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer (TNBC)
Start date
2023-10-07
Primary completion
2027-09-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.